-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

The clinical actionability of clonoSEQ MRD assessment in lymphoid malignancies

Sponsor: Adaptive Bio Therapeutics
Program: Product Theaters
Sunday, December 11, 2022: 11:30 AM-12:30 PM
Hall J - Theater 1 (Ernest N. Morial Convention Center)
Speaker:
Allison Jacob, MS, Adaptive Bio Therapeutics
Disclosures:
No relevant conflicts of interest to declare.
This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

See more of: Product Theaters
<< Previous Product Theater | Next Product Theater >>